Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy

TOKYO , Aug. 19, 2025 /PRNewswire/ -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo ; President & CEO: Rami Suzuki ), a certified startup from the National Cancer Center Japan, has initiated research of YB328 , a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials to evaluate its administration methods and therapeutic efficacy for potential real-world application.

YB328 was identified by a research group led by Dr. Hiroyoshi Nishikawa , Chief of the Division of Cancer Immunology at the National Cancer Center Research Ins

See Full Page